Hyungtaek Jeon,
Global Product Manager,
Xcell Therapeutics Inc.
Education: Mar. 2009 - Feb. 2014: B.S. Dept. of Biomedical Laboratory Science, Eulji University. South Korea Mar. 2014 - Feb. 2018: M.S.& Ph.D. Completion Dept. of Medicine, Eulji University, South Korea Mar. 2018 - Feb. 2021: Technical Research Personnel Dept. of Medicine, Eulji University, South Korea Mar. 2021: Ph.D. Dept. of Medicine, Eulji University, South Korea
Dissertation Title: M.S. & Ph.D. Thesis: “Extracellular Vesicles From KSHV-Infected Cells Stimulate Antiviral Immune Response Through Mitochondrial DNA.” (Mentor: Myung-Shin Lee, M.D., Ph.D.)
Work Experience: 2014. 3 - 2018. 2: Research Fellow, Dept. of Medicine, Eulji University, South Korea 2018. 3 - 2021. 2: Technical Research Personnel (Alternative Military Service), Dept. of Medicine, Eulji University, South Korea 2021.3 - 2023.3 ExoCoBio Inc, South Korea Department of R&D, Team Exosome engineering, Team leader, South Korea 2023.4 - present Xcell Therapeutics Inc., South Korea Department of Sales & Marketing, Global Product Manager, Team leader
Animal-Origin-Free Chemically Defined Media for Human MSC and Serum-Free Chemically Defined Media for Exosome Isolation: Revolutionary Advances in Stem Cell and Exosome Research
Monday, 13 November 2023 at 17:00
Add to Calendar ▼2023-11-13 17:00:002023-11-13 18:00:00Europe/LondonAnimal-Origin-Free Chemically Defined Media for Human MSC and Serum-Free Chemically Defined Media for Exosome Isolation: Revolutionary Advances in Stem Cell and Exosome ResearchExtracellular Vesicles and Nanoparticle-based Therapeutics Europe 2023 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Xcell Therapeutics introduces two groundbreaking products that aim to revolutionize human mesenchymal stem cell (hMSC) research and exosome isolation. The first product CellCor™ MSC CD AOF is Animal-Origin-Free Chemically Defined Media for Human MSC, which significantly improves cell proliferation, reduces senescence, and demonstrates minimal variation compared to fetal bovine serum (FBS) media and other Chemically defined media.
The second product is a serum-free, chemically defined medium developed for the expansion and isolation of hMSC-derived exosomes called for CellCor™ EXO CD. This innovative medium offers safety, efficiency, stability, and purity, producing higher volumes of extracellular vesicles (EVs) with reduced background particles. Additionally, our novel approach allows for efficient recovery of high-potency exosomes without the need for media change, thereby optimizing exosome collection. Overall, these breakthrough products have the potential to drive advancements in stem cell and exosome research, facilitating discoveries and applications in regenerative medicine and therapeutics.
Add to Calendar ▼2023-11-13 00:00:002023-11-14 00:00:00Europe/LondonExtracellular Vesicles and Nanoparticle-based Therapeutics Europe 2023Extracellular Vesicles and Nanoparticle-based Therapeutics Europe 2023 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2023-11-13 17:00:002023-11-13 18:00:00Europe/LondonAnimal-Origin-Free Chemically Defined Media for Human MSC and Serum-Free Chemically Defined Media for Exosome Isolation: Revolutionary Advances in Stem Cell and Exosome ResearchExtracellular Vesicles and Nanoparticle-based Therapeutics Europe 2023 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
